金河生物: 监事会关于2023年限制性股票激励计划相关事项的核查意见

Core Viewpoint - The supervisory board of Jinhe Biotechnology Co., Ltd. has reviewed and approved the conditions for the release of restricted stock under the 2023 Restricted Stock Incentive Plan, confirming compliance with relevant laws and regulations [1][3]. Summary by Sections Section 1: Review of Incentive Objects - The company meets the conditions for implementing the stock incentive plan as per the Management Measures and relevant regulations, confirming the eligibility of the incentive objects for the second release period and the first reserved grant period [1][2]. - The incentive objects for the current plan do not fall under any disqualifying conditions as outlined in the Management Measures [2]. Section 2: Approval of Release Conditions - The supervisory board has verified that the 70 initial incentive objects and 11 reserved incentive objects meet the conditions for the release of restricted stocks, with a total of 4,326,000 shares for the initial grant and 500,000 shares for the reserved grant approved for release [3]. Section 3: Repurchase and Cancellation of Restricted Stocks - The supervisory board has determined that 43 incentive objects did not fully meet performance targets, leading to the repurchase and cancellation of their unvested restricted stocks, totaling 2,100,000 shares [3][5]. - The repurchase price adjustment and the process for cancellation have been confirmed to comply with relevant regulations, ensuring no harm to the company or shareholders [4][5].